

On October 23rd, at the EGM of shareholders, the merger agreement between Celltrion, Inc. & Celltrion Healthcare Co., Ltd. was approved Celltrion...


KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (TOKYO:6594) (OTC US:NJDCY) today announced its consolidated financial results under the International Financial Reporting Standards (“IFRSâ€) for the...


KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Companyâ€) today announced differences between its financial forecast for the six months...


Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed objective response rate of 49.0% and median...


Mindtech’s Digital DNA technology creates a diverse range of Digital Humans that allow for statistically fair representation of the eight billion real...


ANKARA, Turkiye–(BUSINESS WIRE)–#APO–Turkiye, the Asian Productivity Organization’s (APO’s) newest member, generously hosted the 64th Workshop Meeting (WSM) of Heads of National Productivity...


HONG KONG–(BUSINESS WIRE)–Covation Holdings Limited, the global manufacturer of multiple wheeled goods brands, today announced the addition of a new global corporate...


BRISBANE, Australia & BOSTON–(BUSINESS WIRE)–Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has appointed Sami Jaghbir as Underwriting Manager, Queensland. “Sami...


– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfortumab...


Encouraging overall response rate of 46% and disease control rate of 98% with a median duration of response of 11.2 months seen...